NextCure (NASDAQ:NXTC) Given a $15.00 Price Target by Piper Sandler Analysts

NextCure (NASDAQ:NXTC) received a $15.00 target price from equities research analysts at Piper Sandler in a research report issued to clients and investors on Tuesday, MarketBeat reports. The firm presently has an “overweight” rating on the stock. Piper Sandler’s price target would suggest a potential upside of 211.20% from the company’s current price.

A number of other analysts have also issued reports on NXTC. LADENBURG THALM/SH SH upgraded NextCure to a “hold” rating in a research note on Tuesday, July 8th. HC Wainwright reiterated a “buy” rating and set a $36.00 price objective on shares of NextCure in a research note on Tuesday, July 1st.

NextCure Trading Up 1.3%

NXTC stock opened at $4.82 on Tuesday. The stock’s fifty day simple moving average is $5.67 and its two-hundred day simple moving average is $6.92. NextCure has a 1-year low of $2.69 and a 1-year high of $21.48. The stock has a market cap of $12.92 million, a P/E ratio of -0.23 and a beta of 1.06.

NextCure (NASDAQ:NXTC) last issued its earnings results on Thursday, May 1st. The company reported ($4.68) earnings per share (EPS) for the quarter, beating the consensus estimate of ($4.80) by $0.12. As a group, analysts forecast that NextCure will post -1.87 earnings per share for the current fiscal year.

Hedge Funds Weigh In On NextCure

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NXTC. Pfizer Inc boosted its holdings in shares of NextCure by 29.7% in the 1st quarter. Pfizer Inc now owns 1,891,763 shares of the company’s stock worth $909,000 after purchasing an additional 433,213 shares in the last quarter. Renaissance Technologies LLC boosted its holdings in shares of NextCure by 27.9% in the 4th quarter. Renaissance Technologies LLC now owns 519,300 shares of the company’s stock worth $400,000 after purchasing an additional 113,300 shares in the last quarter. Tang Capital Management LLC boosted its holdings in shares of NextCure by 7.3% in the 4th quarter. Tang Capital Management LLC now owns 700,000 shares of the company’s stock worth $540,000 after purchasing an additional 47,614 shares in the last quarter. Finally, Citadel Advisors LLC boosted its holdings in shares of NextCure by 40.6% in the 4th quarter. Citadel Advisors LLC now owns 78,678 shares of the company’s stock worth $61,000 after purchasing an additional 22,724 shares in the last quarter. 42.65% of the stock is currently owned by hedge funds and other institutional investors.

About NextCure

NextCure, Inc, a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells.